Cohance Lifesciences Limited Intrinsic Value
COHANCE · Healthcare · Current price ₹462.35
Is Cohance Lifesciences Limited undervalued?
We estimate the fair value of Cohance Lifesciences Limited at ₹90 per share, against a market price of ₹440. That puts the share price about -79.6% above our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 1 method: Fair multiple (P/E) (₹90). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Cohance Lifesciences Limited spans ₹81 to ₹98. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Margin of safety
Value investors look for a margin of safety: a discount to estimated value that absorbs being wrong. At ₹440 against an estimated value of ₹90, Cohance Lifesciences Limited trades at -79.6%, i.e. a premium to our estimate. How much margin to demand depends on how much you trust the inputs, which is what the confidence band below is for.
How we got this fair value
Every number below is part of the same estimate for Cohance Lifesciences Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹81 – ₹98
Why this method for this business
Relative P/E and EV/EBITDA are most appropriate for a pharmaceutical CDMO with durable moats and stable cash flows. DCF is less suitable due to the complexity of forecasting drug development and regulatory risks.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
required inputs missing
- dcf: forecasting drug development and regulatory risks is too uncertain for a DCF model
- ev_ebitda: used to complement P/E and provide a cross-check on valuation
What was missing
- Lack of forward-looking analyst estimates for EBITDA and EPS
- Limited data on long-term growth prospects beyond 2028
What drives it
15 inputs, grouped by how strong each claim is
- Sector-median P/E
- 38.15×
- Peers used
- 42
- EPS (TTM)
- 2.78 ₹/share
- Own-history median P/E
- 34.13×
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Term: quality
- +1.7%
- Term: growth
- -18.2%
- Term: capital_allocation
- -4.9%
- Term: financial_strength
- +9.0%
- Term: history
- -3.2%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 62/100 (high, stable returns) → premium (ROCE deteriorating → premium halved)
weak ~1% CAGR (ROCE 32% > hurdle) → discount
capital allocation: falling ROCE / weak cash generation → discount
financial strength: effectively debt-free → premium
history: market paid -11% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- -15.6%
- Fair-multiple confidence
- 76%
- Fair P/E
- 32.21×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Cohance Lifesciences Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Cohance Lifesciences Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.